NADA 048-480

DOSAGE FORM

Type A Medicated Feed

ROUTE OF ADMINISTRATION

Oral

RECOMMENDED DOSAGES:

CHICKENS

Dosage             Indication for use
_____________      ________________________________________________
10-50 g/t          Broiler/fryer chickens:
                   For an increased rate of weight
                   gain and improved feed efficiency.
                              
100-200 g/t        Control of infectious synovitis caused by
                   Mycoplasma synoviae susceptible to
                   chlortetracycline. 
                   (Feed continuously for 7 to 14  days )
                   
200-400 g/t        Control of chronic respiratory disease (CRD)
                   and air sac infection caused by Mycoplasma
                   gallisepticum and Escherichia coli susceptible to
                   chlortetracycline.
                   (Feed continuously for 7 to 14  days)

WARNING: Do not feed to chickens producing eggs for human consumption. Withdraw 24 hours prior to slaughter.

CHICKENS

Dosage             Indication for use
_____________      ________________________________________________
500 g/t            Reduction of mortality due to Escherichia coli
                   infections susceptible to chlortetracycline.
                   (Feed for 5 days)

WARNING:  Do not feed to chickens producing eggs for human consumption.  
          Withdraw 24 hours prior to slaughter.


TURKEYS

Dosage             Indication for use
_____________      ________________________________________________
10-50 g/t          Growing turkeys: For an increased rate of
                   weight gain and improved feed efficiency.

200 g/t            Control of infectious synovitis caused by
                   Mycoplasma synoviae susceptible to
                   chlortetracycline.
                   (Feed continuously for 7 to 14 days)
                   
400 g/t            Control of hexamitiasis caused by Hexamita
                   meleagrides susceptible to chlortetracycline.
                   (Feed continuously for 7 to 14 days)
                   
                   Turkey poults not over 4 weeks of age: Reduction of
                   mortality due to paratyphoid caused by Salmonella
                   typhimurium susceptible to chlortetracycline.
                    
25 mg/pound        Control of complicating bacterial organisms
body weight        associated with bluecomb (transmissible enteritis,
daily              coronaviral enteritis) susceptible to chlortetracycline.
                   (Feed continuously for 7 to 14 days)
                    

WARNING: Do not feed to turkeys producing eggs for human consumption.
         Withdraw 24 hours prior to slaughter.


SWINE

Dosage             Indication for use
_____________      ________________________________________________
10-50 g/t          Growing swine: For an increased rate of weight
                   gain and improved feed efficiency.
                   
50-100 g/t         Reducing the incidence of cervical lymphadenitis
                   (jowl abscesses) caused by Group E  Streptococci 
                   susceptible to chlortetracycline.

400 g/t            Breeding swine: Control of leptospirosis (reducing
                   the instances of abortion and shedding of leptospirae) 
                   caused by Leptospira pomona susceptible 
                   to chlortetracycline.
                   (Feed continuously for 14 days)
                   
10 mg/lb           Treatment of bacterial enteritis caused by
body weight        Escherichia coli and Salmonella choleraesuis and
daily              bacterial pneumonia caused by caused Pasteurella
                   multocida susceptible to chlortetracycline.
                   (Feed for not more than 14 days)
                
WARNING: Five-Day Withdrawal period.


CALVES, BEEF CATTLE, AND NON-LACTATING DAIRY CATTLE

WARNING: A WITHDRAWAL PERIOD HAS NOT BEEN ESTABLISHED FOR THIS PRODUCT IN PRE-
         RUMINATING CALVES.  DO NOT USE IN CALVES TO BE PROCESSED FOR VEAL.


Dosage             Indication for use
_____________      ________________________________________________

0.1 mg/pound       Calves (up to 250 lbs.): For an increased rate of
body weight        weight gain and improved feed efficiency.
daily          

25-70 mg/          Calves (250-400 lbs.): For an increased rate of
head/day           weight gain and improved feed efficiency.

70 mg/             Growing cattle (over 400 lbs.): For an increased 
head/day           rate of weight gain, improved feed efficiency
                   and reduction of liver condemnation due to liver abscesses.
                
WARNING: Zero-day withdrawal period

Dosage             Indication for use
_____________      ________________________________________________

350 mg/            Cattle: For the control of bacterial pneumonia
head/day           associated with shipping fever complex susceptible
                   to chlortetracycline.
                   
350 mg/            Beef cattle (under 700 lbs.): Control of active
head/day           infection of anaplasmosis caused by Anaplasma
                   marginale susceptible to chlortetracycline.
                   
0.5 mg/            Beef cattle (over 700 lbs.): Control of active 
pound              infection of anaplasmosis caused by 
daily              Anaplasma marginale susceptible to
                   chlortetracycline.
                   
WARNING: Withdraw 48 hours prior to slaughter.


Dosage             Indication for use
_____________      ________________________________________________

10 mg/pound        For calves, beef, and non-lactating dairy cattle:
body weight        Treatment of bacterial enteritis caused by
daily              Escherichia coli and bacterial pneumonia caused
                   by Pasteurella multocida organisms susceptible to
                   chlortetracycline. 
                   (Treat for not more than 5 days)
                   
WARNING: Withdraw 10 days prior to slaughter.

IV. EFFECTIVENESS:

The drug was the subject of National Academy of Science/National Research Council (NAS/NRC) reports which were published in the FEDERAL REGISTER of July 21, 1970 (35 FR 11647). The Academy evaluated these products as probably effective for growth promotion and feed efficiency and the treatment of animal diseases caused by pathogens sensitive to chlortetracycline.

The Academy states that: (1) Claims made regarding "for prevention of" or "to prevent" should be replaced with "as an aid in the control of" or "to aid in the control of"; (2) claims for growth promotion or stimulation are disallowed and claims for faster gains and/or feed efficiency should be stated as "may result in faster gains and/or improved feed efficiency under appropriate conditions"; (3) each disease claim should be properly qualified as "appropriate for use in (name of disease) caused by pathogens sensitive to (name of drug) "; if the disease cannot be so qualified the claim must be dropped; (4) claims pertaining to egg production and hatchability should be changed to "May aid in maintaining egg production and hatchability, under appropriate conditions, by controlling pathogenic microorganisms"; (5) the labels should warn that treated animals must actually consume enough medicated water or medicated feed to provide a therapeutic dosage under the conditions that prevail and, as a precaution, state the desired oral dose per unit of animal weight per day for each species as a guide to effective usage of the preparation in drinking water or feed: and (6) effective blood levels are required for each recommended dosage.

The Food and Drug Administration concurs with the Academy's findings, interpreting the phrase "...cannot be so qualified..." in paragraph (3) to mean "...is not supported by adequate data..." (See Fed. Reg. vol. 35, NO. 140-Tues., July 21, 1970). FDA proceeded to review all available data relating to the effectiveness of products subject to NADA 48-480 to determine which label claims were supported by the requisite proof of effectiveness. That review supported effectiveness only for the control and treatment of certain bacterial diseases susceptible to chlortetracycline pre-mixes in chickens, turkeys, and swine.

Thereafter, the sponsor complied with the evaluation of NAS/NRC and FDA's conclusions in the following manner:

1. Appropriate oral doses for all the allowable species and claims based on milligrams per unit of body weight or grams per ton are on the current labels.

2. Claims pertaining to egg production and hatchablilty have been deleted from the labels.

3. Each disease claim on the label has been properly qualified with the approriate genus and species of bacteria susceptible to chlortetracycline hydrochloride. Disease claims which were not so qualified have been deleted.

4. Claims made for prevention have been revised to read "Control of..." where appropriate.

5. The manufacturer's label carries the warning statement that treated animals must have the medicated feed adjusted to compensate for variation in age and the weight of animals, the nature and severity of disease signs.

6. Claims for growth promotion or stimulation have been removed. Allowable claims are for increased rate of weight gain and improved feed effieciency.

V. ANIMAL SAFETY:

This supplemental NADA satisfies the requirements of section 512 of the Act and demonstrates that CHLORATET 50 Type A Medicated Article when used under its proposed conditions of use, is safe and effective for the labeled indications. The approval provides for use of CHLORATET 50 Type A Medicated Article for the control and treatment of specific diseases in swine, sheep, cattle, calves, chickens, and turkeys.

The "probably effective" finding of the NAS/NRC regarding chlotetracycline hydrochloride which was published in the FEDERAL REGISTER of July 21, 1970, was subsequently reviewed by FDA, resulting in the upgrade to "effective" status with respect to the claims noted in the paragraphs above. The firm submitted revised labeling to conform and, therefore, this supplemental NADA complies with the NAS/NRC evaluation and FDA's conclusions.

When NADA 48-480 was reviewed under NAS/NRC/DESI program, it was an over-the-counter product and this marketing status remains unchanged. Other Chlortetracycline Type A Medicated Article for use in food-producing animals are also currently on the market as over-the-counter products. Therefore, the Center for Veterinary Medicine has concluded that this product should retain over-the-counter marketing status.

Under the Center's supplemental approval policy (21 CFR 514.106(b)(2)), this is a Category ll change. The approval of this change is not expected to have any adverse effect on the safety or effectiveness of this new animal drug and, therefore, did not require a reevaluation of the human food or target animal safety data in the parent application.

Under the Generic Animal Drug and Patent Term Restoration Act of 1988, this approval does not qualify for an exclusivity period under section 512(c)(2)(F)(iii) of the Federal, Food, Drug, and Cosmetic Act (21 U.S.C. 360b (c)(2)(F)(iii)) because the supplemental application does not contain reports of new clinical or field investigations (other than bioequivalence or residue studies) and in the case of food producing animals human food safety studies (other than bioequivalency or residue studies) essential to the approval and conducted or sponsored by the applicant.

NADA	048-480
Sponsor:	A D M Animal Health & Nutrition, Inc. Fort Wayne, Indiana 46801
Generic Name:	Chlortetracycline Pre-mix
Trade Name:	CHLORATET 50
Marketing Status:	Over the Counter (OTC)
Effect of Supplement:	The effect of this Category II supplement is to bring the drug product into compliance with the National Academy of Science/National Research Council/ Drug Efficacy Study Implementation (NAS/NRC/DESI) recommendations.